C-ABL-IN-2
C-ABL-IN-2 is a potent inhibitor of c-Abl. Activation of c-Abl has been implicated in various diseases, notably cancer. c-ABL-IN-2 has the potential for the research of neurodegenerative diseases (amyotrophic lateral sclerosis (ALS) and Parkinson’s disease (PD) and cancer (extracted from patent WO2020260871A1, compound 25) [1]. c-ABL-IN-2 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
Product Specifications
CAS Number
[2574593-54-5]
UNSPSC
12352005
Target
Bcr-Abl
Type
Reference compound
Related Pathways
Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer; Neurological Disease
Assay Protocol
https://www.medchemexpress.com/c-abl-in-2.html
Solubility
10 mM in DMSO
Smiles
O=C(NC1=CN(C(C)C)C=N1)C2=CC=C(C)C(C#CC3=CC=CN=C3)=C2
Molecular Formula
C21H20N4O
Molecular Weight
344.41
References & Citations
[1] Rebecca PAUL, et al. New compounds and methods. Patent WO2020260871A1.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
MDM2, Phosphorylated (Thr218) (Ubiquitin-protein Ligase E3 Mdm2, p53-binding Protein Mdm2, Oncoprotein Mdm2, Double Minute 2 Protein, Hdm2) (MaxLight 490)
MDM2, Phosphorylated (Thr218) (Ubiquitin-protein Ligase E3 Mdm2, p53-binding Protein Mdm2, Oncoprotein Mdm2, Double Minute 2 Protein, Hdm2) (MaxLight 490)